Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold

J Med Chem. 1998 Sep 24;41(20):3782-92. doi: 10.1021/jm970777b.

Abstract

A study on the use of derivatized carbohydrates as C2-symmetric HIV-1 protease inhibitors has been undertaken. L-Mannaric acid (6) was bis-O-benzylated at C-2 and C-5 and subsequently coupled with amino acids and amines to give C2-symmetric products based on C-terminal duplication. Potent HIV protease inhibitors, 28 Ki = 0.4 nM and 43 Ki = 0.2 nM, have been discovered, and two synthetic methodologies have been developed, one whereby these inhibitors can be prepared in just three chemical steps from commercially available materials. A remarkable increase in potency going from IC50 = 5000 nM (23) to IC50 = 15 nM (28) was observed upon exchanging -COOMe for -CONHMe in the inhibitor, resulting in the net addition of one hydrogen bond interaction between each of the two -NH- groups and the HIV protease backbone (Gly 48/148). The X-ray crystal structures of 43 and of 48 have been determined (Figures 5 and 6), revealing the binding mode of these inhibitors which will aid further design.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipates / chemical synthesis*
  • Adipates / chemistry
  • Adipates / pharmacology
  • Animals
  • Cell Line
  • Crystallography, X-Ray
  • HIV Protease / biosynthesis
  • HIV Protease / isolation & purification
  • HIV Protease / metabolism*
  • HIV Protease Inhibitors / chemical synthesis*
  • HIV Protease Inhibitors / chemistry
  • HIV Protease Inhibitors / pharmacology
  • HIV-1 / drug effects
  • HIV-1 / enzymology
  • Mice
  • Molecular Mimicry*
  • Peptides / chemistry*
  • Structure-Activity Relationship

Substances

  • Adipates
  • HIV Protease Inhibitors
  • Peptides
  • mannaric acid
  • HIV Protease